Mete KARA, Özün BAYINDIR, FİGEN YARGUCU ZİHNİ, GONCA KARABULUT, SELEN BAYRAKTAROĞLU, Hayriye KOÇANAOĞULLARI, NEŞE ÇELEBİSOY, Fahrettin OKSEL

Granülomatöz polianjiit; hastalık aktivasyonu mu, enfeksiyon mu?

Granülomatöz polianjiit birçok sistemi tutan, hayatı tehdit eden bir hastalıktır. Tedavi stratejileri hastalığı iyileştirdiği gibi enfeksiyonlara yatkınlığı da arttırmaktadır. Enfeksiyonlar tanının ilk yılındaki en önemli ölüm nedenidir. Hastalığın seyrinde görülebilen enfeksiyonlar hastalık aktivasyonu ile ayırıcı tanıda her zaman düşünülmelidir. Ayırıcı tanıda klinik seyir, laboratuvar tetkikleri, patolojik incelemeler ve radyolojik görüntülemeler yardımcı olmaktadır. Granülomatöz polianjiit tanısı ile izlediğimiz olgumuzda hastalık aktivasyonu ile karışabilecek enfeksiyonlara dikkat çekmeye çalıştık.

Granulomatosis with polyangiitis; activation or infection?

Granulomatosis with polyangiitis is a life-threatening disease that affects many systems. Treatment strategies improve the disease but also increase the susceptibility to infections. Infections are the most important cause of death within the first year of diagnosis. The infections that can be seen in the course of the disease should always be considered in the differential diagnosis with disease activation. Clinical course, laboratory examinations, pathological examinations and radiological imaging are helpful in differential diagnosis. With the diagnosis of granulomatous polyangiitis in our case, we tried to draw attention to infections that could be confused with disease activation.

PDF

___

10. Weidanz F, Day CJ, Hewins P, Savage CO, Harper L. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis 2007;50(1):36-46.
9. Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis 2009;68(5):658-63.
8. Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 2015;45(3):346-68.
7. Frary EC, Hess S, Gerke O, Laustrup H. 18F-fluoro-deoxy-glucose positron emission tomography combined with computed tomography can reliably rule-out infection and cancer in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis suspected of disease relapse. Medicine (Baltimore). 2017;96(30):e7613.
6. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70(3):488-94.
5. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): Ten-year experience at a single center. Arthritis Rheum 2012;64(11):3770-8.
4. Holle JU, Gross WL, Latza U, Nolle B, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011;63(1):257-66.
3. Schonermarck U, Gross WL, de Groot K. Treatment of ANCAassociated vasculitis. Nat Rev Nephrol 2014;10(1):25-36.
2. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J 1958;2(5091):265-70.
1. Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am 2010;36(3):447-61.